# Optical Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/optical-biosystems

- Industry: Biotechnology
- Headquarters: Santa Clara, US
- Website: www.rebusbio.com
- Total disclosed funding: $20M
- Latest round: Series B (Nov 19, 2020)
- Investors on record: 8

## About

Optical Biosystems, Inc. is a technology firm focused on innovative biosystems solutions that enhance performance and efficiency in biological applications, primarily serving the biotechnology and life sciences sectors.Optical Biosystems, Inc. provides advanced biosystems solutions tailored for biological research and applications. The company is headquartered in Santa Clara, US. It was founded by Josh Ryu, who has a background in the biotech industry and has previously founded other companies. In November 2020, Optical Biosystems raised USD 20 mn in Series B funding led by Illumina Ventures and supported by several other investors including CTK Investment and Lifecore Partners. This funding round marks the total amount raised by the company to USD 20 mn.The company specializes in providing digital solutions designed to enhance biological research efficiency. Their core offerings include advanced biotech tools, data analytics platforms, and consulting services aimed at improving research accuracy and operational effectiveness. The solutions are primarily targeted at research institutions, pharmaceutical companies, and biotechnology firms across North America and Europe.Optical Biosystems generates revenue through service agreements and subscription-based models tailored for research institutions and commercial entities in the biotech sector. Their pricing structure includes tiered plans based on service features, enabling clients to select packages that suit their specific research needs, which fosters long-term partnerships and enhances client engagement.Optical Biosystems, Inc. plans to expand its product line with new biotech tools scheduled for launch in 2022, aimed at improving research capabilities. The company is targeting expansion into European and Asian markets by 2023, capitalizing on the growing demand for biotech solutions in these regions. Recent funding will support product development and market entry strategies, enhancing their ability to meet the needs of international clients.

## Funding rounds

- Series B, Nov 19, 2020, $20M — Ray Co., Ltd., LabGenomics. Co., Ltd., Illumina Ventures, Time Folio Asset Management, NCORE Ventures, CTK Investment, Lifecore Partners, Seegene Inc.

## Investors

- Ray Co., Ltd. — Series B
- LabGenomics. Co., Ltd. — Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series B
- Time Folio Asset Management — Series B
- NCORE Ventures (https://capitalatlas.ai/funds/ncore-ventures) — Series B
- CTK Investment (https://capitalatlas.ai/funds/ctk-investment) — Series B
- Lifecore Partners — Series B
- Seegene Inc. — Series B